JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v136,p542)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
David H. Sachs
James S. Allan
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, B.-N. H.
Right arrow Articles by Pierson, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, B.-N. H.
Right arrow Articles by Pierson, R. N., III
Related Collections
Right arrow Lung - other
Right arrow Lung - transplantation
Right arrowRelated Article

J Thorac Cardiovasc Surg 2007;133:1354-1363
© 2007 The American Association for Thoracic Surgery

Cardiothoracic Transplantation

Life-supporting function of genetically modified swine lungs in baboons

Bao-Ngoc H. Nguyen, MDa, Agnes M. Azimzadeh, PhDa, Tianshu Zhang, MD, PhDa, Guosheng Wu, MD, PhDa, Henk-Jan Shuurman, PhDb, David H. Sachs, MDc, David Ayares, PhDd,1, James S. Allan, MDc, Richard N. Pierson, III, MDa,*

a University of Maryland and Baltimore Veterans Administration Medical Center, Baltimore, Md
b Immerge Biotherapeutics Inc, Cambridge, Mass
c Transplantation Biology Research Center, Massachusetts General Hospital, Boston, Mass
d Revivicor, Blacksburg, Va.

Read at the Eighty-sixth Annual Meeting of The American Association for Thoracic Surgery, Philadelphia, Pa, April 29–May 3, 2006.

Received for publication April 28, 2006; revisions received November 10, 2006; accepted for publication November 20, 2006.

* Address for reprints: Richard N. Pierson III, MD, Division of Cardiac Surgery, University of Maryland, 22 S Greene St N4W94, Baltimore, MD 21201. (Email: rpierson{at}smail.umaryland.edu).

Objective: During ex vivo perfusion with human blood, homozygous galactosyl transferase knockout swine lungs exhibit prolonged survival (~2 hours) relative to wild-type (<15 minutes) and swine lungs expressing human decay accelerating factor (<1 hour). In this study, the in vivo behavior of galactosyl transferase knockout lungs was evaluated.

Methods: Three galactosyl transferase knockout swine left lungs were transplanted into baboons in a life-supporting model. One baboon lung allograft and two swine lung xenografts transgenic for human membrane cofactor protein (CD46) served as controls.

Results: Whereas two membrane cofactor protein lungs exhibited high pulmonary vascular resistance (>500 mm Hg · min/L) and failed to support life within 21 minutes, two of three galactosyl transferase knockout lungs supported life, for 90 and 215 minutes, and displayed low peripheral vascular resistance (48 ± 12 mm Hg · min/L at 60 minutes), similar to the allogeneic control. Complement activation (delta C3a < 250 ng/mL through 60 minutes) and C5b-9 deposition were minimal in both galactosyl transferase knockout and membrane cofactor protein lungs. Neutrophils, monocytes, and platelets were rapidly sequestered in galactosyl transferase knockout and human membrane cofactor protein lung recipients, unlike the allogeneic control (<20%); and thrombin formation (delta plasma fraction 1+2 > 0.5 nmol/L) was seen in the galactosyl transferase knockout recipients. Platelet activation (ß-thromboglobulin rise > 200) and appearance of capillary congestion and vessel thrombosis confirmed coagulation activation associated with galactosyl transferase knockout lung failure.

Conclusions: Galactosyl transferase knockout swine lungs are significantly protected in vivo from the physiologic consequences (increased pulmonary vascular resistance, capillary leak) associated with hyperacute lung rejection. As during ex vivo perfusion, dysregulated coagulation—thrombin elaboration, platelet activation, and intravascular thrombosis—mediates galactosyl transferase knockout lung xenograft injury.

Abbreviations and Acronyms ßTG = beta-thromboglobulin; ELISA = enzyme-linked immunosorbent assay; F1+2 = fragments 1+2; GalT-KO = galactosyl transferase knockout; hDAF = human decay accelerating factor; hMCP = human membrane cofactor protein; MCP = membrane cofactor protein; PVR = peripheral vascular resistance


Related Article

Discussion
J. Thorac. Cardiovasc. Surg. 2007 133: 1362-1363. [Extract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The American Association for Thoracic Surgery.